09:00 - 13:00
United Kingdom, Germany
09:00 - 13:00
& The Role of Big Pharma
09:00 - 09:20 | Conference Inauguration - Welcome Remarks
09:20 - 09:30 | Malta's Journey
What key drivers were behind the introduction of the production of cannabis for medicinal use act?
09:30 - 09:40 | Research and Development
How has the change in law affected the scientific sector in Malta?
09:40 - 10:00 | The Future of Medical Cannabis
How will a patient-centric approach affect policy and supply chain decisions?
10:00 - 10:10 | Managing Fibromyalgia
What does the latest research say about managing symptoms of fibromyalgia with cannabis?
10:10 - 10:20 | Chronic Pain Management
What is the appropriate use of medical cannabis for patients with chronic pain?
10:20 - 10:30 | Cancer Treatment
Review of the latest research on the use of medical cannabis for the treatment of cancer.
10:30 - 10:40 | Alternative Options
The argument for boosting the body's natural endocannabinoids.
10:40 - 11:00 | WHO and its Impact on National Policies
International organisations such as the World Health Organisation are becoming increasingly vocal on the application of medical cannabis. How is this impacting policy makers at state-level across different continents?
11:00 - 11:10 | Monitoring and Control
What steps are being taken towards standardisation and quality control on a European level?
11:10 - 11:20 | From Cultivation to Waste Disposal
How is Malta enforcing regulatory procedures?
11:20 - 11:30 | Intellectual Property and its Challenges
How can pharmaceutical companies develop an effective intellectual property and commercial strategy for synthetic cannabinoids?
11:30 - 11:50 | Synthetic Cannabinoids
what are the benefits and disadvantages of man-made cannabinoids?
11:50 - 12:00 | Broad Uses of Medical Cannabis
How is the legalisation of botanical-derived medical cannabis and its reputation as a treatment for multiple illnesses affecting the sale of other drugs by pharmaceutical companies?
12:00 - 12:10 | Investment and Big Pharma
There's no doubt pharmaceutical companies have the resources to research, develop and market synthetic cannabinoids. With demand exceeding supply in the market how might they use this to carve out their niche in the industry?
12:10 - 12:20 | A Long Process
Pharmaceutical companies have a notoriously long process to get a drug approved. If they move in the direction of synthetic cannabinoids how can they avoid losing out due to the long and expensive timeline?
12:20 - 12:30 | Social Trends
Medical cannabis is being championed as a natural remedy which can treat a variety of physical and psychological disorders. How might this social shift towards herbal based drugs stack up against the reputation of pharmaceutical companies?
12:30 - 14:00 | Start-up Pitch
10 medical cannabis startups with the most innovative projects will pitch on stage in front of established entrepreneurs and savvy investors . Set your sights on the moon and battle it out in a shark-tank environment with some tough love from a select panel of stern judges.
14:00 - 18:00
Australia, New Zealand,
Asia, LatAm, United States
14:00 - 18:00
& The Start-Up Pitch
14:00 - 14:10 | Case Study
From concept to exit, review of a successful start-up investment.
14:10 - 14:30 | Mergers & Acquisitions
As Big Tobacco and Big Alcohol get involved in the medical cannabis industry, how will this affect global markets?
14:30 - 14:40 | Pick and Shovel Play
How are investors using this strategy to mitigate risk in volatile cannabis stocks?
14:40 - 14:50 | ETFs
What's the advantages of entering the medical cannabis investment market via exchange traded funds?
14:50 - 15:00 | Review
Which are the best medical cannabis stocks and what can future big players learn from them?
15:00 - 15:10 | Economic Sectors
In which other ways does the production of medical cannabis benefit a country's other economic sectors?
15:10 - 15:30 | Fund Restrictions
Depending on the type of funds they have access to, some investors cannot put capital into the cultivation of the crop, only technology and services that are not related to the plant itself. How is this restricting start-ups from getting the capital they need?
15:30 - 15:40 | Mergers & Acquisitions
This is already a feature of the medical cannabis sector. How might it affect its future in Europe?
15:40 - 15:50 | Emerging Markets
How does medical cannabis compare to other emerging markets?
15:50 - 16:00 | Ancilliary Services
What sort of investment is required in ancillary services in order to support the medical cannabis sector?
16:00 - 16:20 | From ICO's to Cannabis
Following the recent pitfall that many investors have experienced with ICO's worldwide, could cannabis pave the way for more secure investment opportunities?
16:20 - 16:30 | Market Overview
What is the European medicinal cannabis market worth and what are the future projections?
16:30 - 16:40 | Funding and Research
Both the public and private sector are investing in scientific research. How can the two work together for both the benefit of patients and future commercial success?
16:40 - 16:50 | Mitigating Risk
Investment firms have highlighted several risk factors in investing in the European medical cannabis industry. How are these to be reduced?
16:50 - 17:10 | VC's and PE
Venture capitalists and private equity funds are heavily involved in the North American medical cannabis market. How does this compare to Europe?
17:10 - 17:20 | Going Public
IPO's are happening in Canada. Will the trend move to Europe?
17:20 - 17:30 | Preventing Exploitation
In markets where medical cannabis is legal and recreational cannabis is not, what measures are in place to stop exploitation?
17:30 - 17:40 | Commercialisation
Since medical cannabis isn't legal everywhere, advertising on social media and other digital platforms is limited. How might this effect an investor's decision on financing start-ups?
17:40 - 17:50 | Traditional Financing Models
How is stigma and uncertainty preventing medical cannabis companies from raising capital from banks and lending institutions and how can this be addressed?
17:50 - 18:00 | Supply and Demand
Cover supply is a problem affecting certain markets. How can a company accurately forecast demand?
18:30 - 20:00 | Networking Drinks
19:00 - 23:00 | VIP Networking Dinner
Viking PC Health Ltd. is a company registered in Malta, having company registration number C54356 and VAT number MT20561207. Copyright Viking PC Health Ltd. All rights reserved © 2011 – 2019.